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Abstract
Hexanucleotide repeat expansions in the C9orf72 gene are the most common cause of 
amyotrophic lateral sclerosis and frontotemporal dementia (c9FTD/ALS). The nucleotide repeat 
expansions are translated into dipeptide repeat (DPR) proteins, which are aggregation-prone and 
may contribute to neurodegeneration. We used the CRISPR-Cas9 system to perform genome-wide 
gene knockout screens for suppressors and enhancers of C9orf72 DPR toxicity in human cells. We 
validated hits by performing secondary CRISPR-Cas9 screens in primary mouse neurons. We 
uncovered potent modifiers of DPR toxicity whose gene products function in nucleocytoplasmic 
transport, the endoplasmic reticulum (ER), proteasome, RNA processing pathways, and in 
chromatin modification. One modifier, TMX2, modulated the ER-stress signature elicited by 
C9orf72 DPRs in neurons, and improved survival of human induced motor neurons from C9orf72 
ALS patients. Together, this work demonstrates the promise of CRISPR-Cas9 screens to define 
mechanisms of neurodegenerative diseases.
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Introduction
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are devastating 
human neurodegenerative disorders. ALS is associated with progressive motor neuron loss 
from the brain and spinal cord, leading to muscle weakness, paralysis, and ultimately death, 
usually 2–5 years after symptom onset 1. FTD, the second most common cause of dementia 
in patients less than 65 years old, is caused by the degeneration of neurons from the frontal 
and temporal lobes of the brain and is associated with a range of cognitive and behavioral 
symptoms, including changes in personality. There is an emerging appreciation for clinical 
overlap between ALS and FTD, with evidence that FTD symptoms can be seen in ALS 
patients and motor neuron signs can be seen in FTD patients 2. The two disorders are also 
connected by pathology and genetics. Aggregates of the RNA-binding protein TDP-43 
accumulate in neurons of nearly all ALS cases and almost half of FTD cases 3 and mutations 
in several genes can cause ALS, FTD, or even both (ALS/FTD) 4. Mutations in one such 
gene, C9orf72, are the most common cause of ALS and FTD 5,6.
The ALS and FTD causing mutation in the C9orf72 gene is a massively expanded 
hexanucleotide repeat (GGGGCC) 5,6, which produces sense and antisense RNA foci 5 and 
is translated into aggregation-prone dipeptide repeat (DPR) proteins through an 
unconventional form of AUG-independent translation (also called RAN translation) 7–10. 
Studies in flies and human cells suggest DPRs may be the main drivers of neuronal toxicity 
11–13
. The arginine-rich DPRs, Glycine-Arginine (GR) and Proline-Arginine (PR) are 
particularly toxic in experimental models 11,13–16. Synthetic PR or GR DPRs added 
exogenously to the culture media are rapidly transported to the nucleus, cause disruptions in 
RNA splicing – including in the canonical splicing and biogenesis of ribosomal RNA 
(rRNA) – and induce cell death in a dose-dependent manner 14. Subsequent studies have 
provided evidence through co-immunoprecipitation and mass-spectrometry that these DPRs 
preferentially bind proteins with low complexity domains, including RNA-binding proteins 
17–19
, ribosomal proteins, and translational elongation factors 20,21, as well as nuclear pore 
complex components 22.
Genetic screens in simple experimental model organisms like yeast, flies, and worms have 
empowered the discovery of fundamental biological processes including mechanisms of 
human disease 23. For example, we and others have used genetic screens in model systems 
to identify modifiers of toxicity elicited by aggregation-prone neurodegenerative disease 
proteins, such as TDP-43, FUS, Amyloid-β, alpha-synuclein, mutant huntingtin, and 
C9orf72 DPRs 15,16,24–34. Underscoring the impact of these simple model systems, some of 
the modifier genes from the genetic screens have been validated in mouse models and even 
connected to human disease through genetics and neuropathology 35–37.
While model systems have been powerful experimental tools for the study of human 
neurodegenerative disease mechanisms, it would be empowering to have access to the 
human genome to perform similar modifier screens in human cells. Recent technological 
advances in CRISPR-Cas9 genome editing have expanded the scope and reliability of 
genome-wide genetic deletion screens to the human genome using high complexity single-
guide RNA (sgRNA) libraries 38–42. Here, we used the CRISPR-Cas9 system to perform 
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comprehensive genome-wide knockout screens in human cells and mouse primary neurons 
to identify genetic modifiers of C9orf72 DPR toxicity.
Results
CRISPR-Cas9 screens for C9orf72 DPR toxicity modifiers
We engineered the human immortalized myelogenous leukemia cell line, K562, to stably 
express Cas9 43. We picked this cell line for the initial screen for several reasons. The cells 
grow in suspension and double rapidly, allowing us to expand the cultures to large numbers 
that are required to perform genome-wide screens with complex sgRNA libraries. 
Furthermore, this cell line has been used for several other genome-wide screens, allowing us 
to compare and contrast hits to test for specificity. Similar to previous reports in other human 
cell lines 14, synthetic polymers of PR and GR (PR20 and GR20) added to cell culture media 
were rapidly taken up by K562 cells, trafficked to the nucleus, and killed cells in a dose-
dependent manner (Fig. 1a–d, Fig. S1a).
To identify genetic modifiers of both PR20 and GR20 mediated-toxicity, we conducted 
genome-wide CRISPR knockout screens. We used a lentiviral sgRNA library comprised of 
ten sgRNAs per gene, targeting ~20,500 human genes, along with ~10,000 negative control 
sgRNAs 44 (Fig. 1e). We used deep sequencing to track the effect (protective, sensitizing, 
neutral) of each sgRNA in a pooled population of knockout cells. That is, sgRNAs that 
protected cells from DPR toxicity were enriched and those that sensitized cells were 
depleted from the pooled population of cells. In order to identify both protective and 
sensitizing gene knockouts in the same screen, we treated the pooled population of cells with 
a dose of the DPR sufficient to kill 50% of cells and repeated this treatment four times over 
the course of the screen to amplify the selection. We performed separate screens for 
modifiers of PR20 and GR20 toxicity, each in duplicate, and repeated each screen two 
independent times.
To detect statistically significant suppressors and enhancers of DPR toxicity we used the 
casTLE algorithm as previously described 45. Using a false discovery rate (FDR) cut-off of 
10%, the screens identified 215 genetic modifiers of PR20 toxicity and 387 genetic modifiers 
of GR20 toxicity (Fig. 1f, S2a–c, Supplementary Table 1). Results from the PR20 and the 
GR20 screen were well correlated (R2=0.61), suggesting similar mechanisms of toxicity 
(Fig. 1g). We validated individual knockout K562 lines by performing competitive growth 
assays with PR20 treatment. We tested five genes from the primary screen (two guides per 
gene) and all five genes validated in these assays (Fig. 1h). Furthermore, to assess the 
specificity of our screens, we compared the hits from our genome-wide screens to the hits 
from a similar screen performed for ricin toxicity, which used the same cell line, sgRNA 
library, and method of exogenous application of a toxic protein 44. We found zero correlation 
between hits in the two screens (R2 = 0), indicating that we are uncovering specific genetic 
modifiers, rather than non-specific genes involved in general peptide-mediated toxicity (Fig. 
S2d).
Among the hits from these knockout screens were genes encoding some of the same nuclear 
import and export factors discovered in DPR modifier screens in model organisms 15,16,46,47, 
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such as XPO6 and IPO11 (Fig. 2), suggesting the same mechanisms are important in 
mammalian cells. In addition, we identified many novel genetic modifiers of PR and GR 
toxicity, including genes encoding RNA-binding proteins that have been shown to physically 
interact with PR and GR 17, such as NONO and HNRNPF. We also identified genes 
involved in RNA-splicing, such as SPEN and PQBP1, a process previously observed to be 
dysregulated in c9FTD/ALS patient brains 48 and dramatically disrupted in human cell lines 
treated with DPRs 14. In addition to these previously implicated genes, some of the strongest 
hits in the screen encoded endoplasmic reticulum (ER)-resident proteins, such as TMX2, 
CANX, and almost all members of the ER membrane protein complex (EMC), which is 
upregulated by ER stress and is thought to be involved in ER-associated degradation 
(ERAD) 49–51. Genes encoding proteasome subunits, as well as chromatin modifiers and 
transcriptional regulators, such as those involved in histone lysine methylation (KDM6A, 
KMT2D, KMT2A, and SETD1B) were also significant genetic modifiers of PR and GR 
toxicity (Fig. 2).
CRISPR-Cas9 screens in primary mouse neurons
To evaluate the role of the genetic modifiers identified in our human genome-wide screens in 
a more disease relevant context, we next designed a strategy to conduct pooled CRISPR-
Cas9 screens in mouse primary cortical neurons. Similar to human cell lines, synthetic PR20 
dipeptides were toxic to primary neurons in a dose-dependent manner (Fig. 3a). However, to 
better model the endogenous production of DPRs, like in patient brains, we also used a 
lentiviral construct expressing codon optimized PR50 driven by the neural-specific synapsin 
promoter 52. When expressed in primary neurons, PR50 localized to nuclear puncta and 
elicited neurotoxicity in a time-dependent manner (Fig. 3b, S3a). We constructed a custom 
lentiviral sgRNA library to test the top ~200 genes (5% FDR) that were modifiers of PR20 
toxicity in the genome-wide CRISPR screens. The custom library contained ten sgRNAs 
targeting each mouse gene and ~1,000 negative control sgRNAs. Using primary neuron 
cultures isolated from mice constitutively expressing Cas9 53, we used immunoblotting to 
confirm efficient protein reduction of target genes after transduction with sgRNAs from this 
library following at least 10 days in culture (Fig. S4 a–c).
We performed the primary neuron CRISPR screens two ways: either expressing PR50 in 
neurons using lentivirus or treating neurons with exogenous synthetic PR20 (Fig. 3c). In this 
way, we could simultaneously validate hits from the genome-wide screens and disentangle 
the genes responsible for the uptake and spread of the DPRs throughout the cell from those 
responsible for mediating the toxic effects once inside the cell. We performed these targeted 
CRISPR KO screens such that there was a ~90% reduction in viability after one round of 
selection. Given the stringency of this screen, together with the fact that these neurons are 
non-dividing, we would only expect genetic modifiers with the strongest effects to become 
enriched. We harvested the surviving neurons and assessed sgRNA enrichment compared to 
the control populations by deep sequencing (Fig. 3c). We identified 13 modifier genes in the 
synthetic PR20 screen and 17 genes in the lentiviral PR50 expression screen (determined by 
having a non-zero estimated effect with a 95% credible interval) (Fig. 3d, e, S4d, 
Supplementary Table 2). The genes that validated in these neuronal cultures showed strong 
specificity to the method of PR delivery to the neurons. We further validated the two 
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strongest modifier genes from these neuronal screens in an independent primary neuron 
culture model of DPR toxicity, using mouse dorsal root ganglion neurons. Knockout of 
either Rab7 or Tmx2 protected against PR toxicity in these primary neurons (Fig. 4a–d).
RAB7A and intracellular transport of PR20
A top hit in the screen for modifiers of synthetic PR20-induced toxicity was the endo-
lysosomal trafficking gene, RAB7A (Fig. 3d). We hypothesized that the endosomal 
trafficking pathway is necessary for the intracellular transport of exogenously applied PR20. 
We tested this hypothesis in WT and RAB7A knockdown HeLa cells by 
immunocytochemistry and found altered subcellular localization of PR20 (Fig. S3b), 
indicating that endo-lysosomal trafficking is important for the localization and subsequent 
toxicity of synthetic PR20. We used the CRISPR-i system to reduce levels of RAB7A in 
HeLa cells. This caused a stereotypical enlargement and mislocalization of LAMP1 positive 
lysosomal puncta. In control cells, at an early time point after PR20 addition (1hr, 1μM 
PR20), PR20 distributed diffusely throughout the cell, including the nucleus but was not yet 
enriched in the nucleus, as in Fig. 1b,d, S1. However, at this same early time point in 
RAB7A knockdown cells (Rab7-i.1), PR20 accumulated in numerous puncta speckled 
throughout the cytosol, indicative of an early endomembrane compartment (Fig. S3b). Since 
cell-to-cell spread of DPRs is possibly relevant to disease 54,55, understanding mechanisms 
of DPR cellular entry and trafficking could inform strategies to block this process.
C9orf72 DPRs induce an ER stress response
In contrast to the screen with synthetic PR20, none of the trafficking genes present in the 
mini-library were hits in the screen in which neuronal toxicity was induced by lentiviral 
mediated PR50 expression. In this screen, the strongest genetic modifiers were genes that 
encode proteins predominantly localized to the nucleus and ER; a top protective knockout 
was a poorly characterized ER-resident transmembrane thioredoxin protein, Tmx2 (Fig. 3e). 
Since this strongest hit was implicated in ER function, it suggested that DPR accumulation 
might induce an ER stress response. To test this hypothesis, we performed RNA sequencing 
(RNA-seq) on primary neuron cultures transduced with a lentivirus expressing either PR50 
or GFP (Fig. 5a). Following four days of PR50 expression, 126 genes were significantly 
upregulated and 133 genes significantly downregulated (DESeq2, adjusted p-value < 0.05; 
Fig. 5b, S5, Supplementary Table 3). A significantly enriched Gene Ontology (GO) category 
among upregulated genes was ‘apoptotic signaling pathway in response to endoplasmic 
reticulum stress, GO:0070059’ (Fig. 5c). Genes in this enriched ontology category included 
Atf4, Bbc3 (Puma), Chac1, Bax, and the ER Ca2+ channel Itpr1, in which loss of function 
variants have been shown to cause spinocerebellar ataxia 56 (Fig. 5d). Other notable enriched 
GO categories among these differentially expressed genes included ‘neuronal apoptosis’, 
‘ion homeostasis’, ‘ribonucleoprotein’, ‘translation’, and ‘DNA repair’.
Based on these RNA-seq results, we confirmed a time dependent induction of ER stress 
related genes by PR50 expression using quantitative reverse transcription PCR (qRT-PCR) 
(Fig. 5e). The IRE1 stress sensor of the unfolded protein response was not activated by PR50 
expression in neurons, as measured by levels of spliced XBP1 mRNA (Fig. 5h). These data 
are consistent with activation of the integrated stress response, which converges on eIF2 and 
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the upregulation of transcription factor ATF4 57. To confirm that these ER stress responses 
are conserved in other models of DPR toxicity we performed RNA-seq on primary mouse 
neurons as well as human K562 cells, each treated with synthetic PR20. ATF4 and related 
ER stress response genes were also induced in each of these models (Fig. 5f, S6, 
Supplementary Table 3). Finally, in addition to observing genetic signatures of ER stress, we 
also used a pharmacological approach to test the importance of this pathway in response to 
PR20. The small molecule ISRIB is a potent inhibitor of the cellular response to ER stress 58, 
preventing ATF4 induction by inhibiting eIF2α phosphorylation during the integrated stress 
response 59. Pre-treatment of K562 cells with 15nM ISRIB mitigated PR20 toxicity (Fig. 
5g), providing further evidence for a role of ER stress in DPR-mediated toxicity. Future 
experiments will be required to validate ISRIB’s efficacy in primary neurons and animal 
models of C9orf72 DPR toxicity.
TMX2 modifies the C9orf72 DPR-induced ER stress response
Several lines of evidence have suggested a potential role for ER stress in C9orf72 
pathogenesis. Transcriptomic analysis of C9orf72 mutant ALS brain tissue reveals an 
upregulation of genes involved in the unfolded protein response (UPR) and ER stress 48. A 
specific PERK-ATF4 mediated ER stress response was reported in a separate study of 
c9ALS/FTD patient brain tissue when compared to sporadic ALS patient brain tissue 60. 
Additionally, ER stress and disruptions to ER Ca2+ homeostasis were observed in 
c9ALS/FTD patient iPSC-derived motor neurons 61. Given that a main transcriptional stress 
response to endogenous and exogenous DPR treatment was the ER stress response, we chose 
to further investigate TMX2, a gene encoding a poorly characterized ER-resident protein 
that was one of the strongest protective hits in both the PR and GR genome-wide CRISPR 
screens in K562 cells and in the targeted primary neuron screen expressing PR50. We first 
confirmed that the sgRNAs targeting TMX2 effectively knocked out the gene in K562 cells 
and primary neurons cultured from the Cas9-expressing mouse (Fig. 6a, S7a). Strikingly, 
reduction of TMX2 levels was sufficient to markedly suppress C9orf72 DPR toxicity both in 
K562 cells (Fig. S7b) and in primary mouse cortical neurons (Fig. 6b, c).
TMX2 is an ER resident transmembrane thioredoxin protein that may be enriched at the 
mitochondrial-associated membrane (MAM) of the ER 62. It is a member of the protein 
disulfide isomerase (PDI) family, but it is unclear whether it is catalytically active since it 
harbors an SXXC motif instead of the canonical CXXC motif necessary for the 
oxidoreductase activity used to catalyze the formation or rearrangement of disulfide bonds 
63
. To define the mechanism by which Tmx2 reduction mitigates DPR toxicity, we 
performed RNA-seq on primary Cas9+ neurons infected with control sgRNAs (Safe) or 
sgRNAs targeting Tmx2, with or without PR50 expression (Fig. 6d, e, S7c–h). Upon PR50 
expression, Tmx2 KO neurons upregulated a distinct set of pro-survival unfolded protein 
response (UPR) pathway genes and downregulated calcium-binding and apoptotic genes, 
compared to primary neurons expressing control sgRNAs (Fig. 6d, e, Supplementary Table 
3). We validated, by qRT-PCR, one of the upregulated ER stress genes that we observed in 
the Tmx2 KO neurons after PR50 expression, Atf3, which has been previously shown to be 
protective upon overexpression in mouse models of ALS 64 and neuronal models of 
excitotoxicity 65 (Fig. 6f). These results suggest that Tmx2 reduction may be protective by 
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modulating the ER stress response elicited by the DPRs. Indeed, upregulation of Atf3 alone 
was sufficient to protect primary cortical neurons from PR toxicity (Fig. 6g–i).
Lowering TMX2 improves survival of C9-ALS motor neurons
Given the strong protective effect of Tmx2 knockdown on PR mediated toxicity in rodent 
primary neurons, we tested whether lowering TMX2 levels could modify survival 
phenotypes in neuronal cells from ALS patients harboring endogenous C9orf72 GGGGCC 
expansions. We generated induced motor neurons (iMNs) from iPSCs from C9orf72 ALS 
patients and healthy subjects using transcription factor-mediated lineage conversion as 
previously described 13,66. These C9-ALS patient derived iMNs show reduced survival after 
glutamate addition compared to control iMNs (Fig. 7, S8, and 13). Using a seven factor (7F) 
differentiation method to generate iMNs, we tested two independent shRNAs targeting 
TMX2, and found that both shRNAs significantly increased the proportion of surviving 
C9orf72 iMNs compared to control shRNAs in two independent C9-ALS lines (Fig. 7a, b), 
but did not increase the proportion of surviving control iMNs (Fig. S8). We repeated this 
experiment using a different differentiation method (Dox-NIL) to generate iMNs, and found 
a similar protective effect of TMX2 reduction in C9-ALS but not control iMNs, though there 
was a degree of variability of the extent of rescue between patient lines with this 
differentiation method (Fig. S9). Further studies will be required to assess the effect of 
TMX2 on C9orf72 related pathologies in additional patient cell lines and ALS models, but 
these results suggest our screening strategy may be useful to identify potent modifiers of 
ALS-related phenotypes.
Discussion
Here, we used comprehensive CRISPR-Cas9 knockout screens in human cells with further 
validation screens in primary neurons to discover modifiers of C9orf72 DPR toxicity. We 
identified nucleocytoplasmic transport machinery, confirming previous studies in model 
organisms 15,16, and also identified new genes that point to ER function and ER stress as 
important for c9FTD/ALS pathogenesis. The gene knockouts that mitigated toxicity, such as 
TMX2, could represent therapeutic targets. It is notable that TMX2 reduction was able to 
confer strong protection from PR toxicity across multiple cellular assays, including primary 
rodent neurons.
There are five distinct DPRs produced from the C9orf72 GGGGCC repeat expansion: 
Glycine-Alanine (GA), Glycine-Arginine (GR), Glycine-Proline (GP), Proline-Alanine (PA), 
and Proline-Arginine (PR) (GP is produced from both the sense and antisense transcript). 
Our studies here have focused on two of these, GR and PR. The relative contribution of each 
DPR to neurodegeneration and the potential for synergistic effects between multiple DPRs 
remains to be defined. While the evidence from model systems for a role of DPRs in 
neurodegeneration is compelling, there are some caveats. These studies, including ours, use 
synthetic DPRs exogenously added to cells or high levels of transgenic expression of 
specific DPRs, which might not accurately reflect the physiological levels of DPRs. 
Moreover, studies of c9FTD/ALS neuropathology have also produced results that seem to 
not support a role of DPRs as the drivers of neurodegeneration. The abundance and 
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localization of DPR pathology does not seem to correlate with neurodegeneration and 
clinical phenotypes 67–71. Finally, GA and GP DPRs seem to be the most abundant but these 
ones are the least toxic in model systems 11,15,16. On the other hand, the most toxic DPR, 
PR, is extremely rare 70. One possible explanation for this apparent disconnect is that the 
most toxic DPRs (e.g., GR and PR) do not accumulate to high enough levels (because they 
are so toxic) before causing neuron death whereas the other ones (e.g., GA and GP) can 
accumulate to higher levels because they are more benign 72.
Beyond the DPRs, RNA foci from the sense (GGGGCC) and antisense (GGCCCC) repeat 
transcripts, as well as loss of function of the C9orf72 gene could also contribute to disease. 
These different mechanisms could also interact with one another. For example, loss of 
C9orf72 function could make neurons or glia more vulnerable to the RNA foci or DPRs. 
Additionally, our work here provides evidence that DPRs can elicit an ER stress response 
and recent work shows that ER stress can increase RAN translation 73,74 – setting up the 
potential for a feedforward loop. It will be important to define the relative contributions of 
each of these facets of C9orf72 pathology (loss of function, RNA foci, DPRs) to disease so 
that effective therapeutic strategies can be developed. If the DPRs are indeed key 
contributors to disease, our work here identifies novel suppressors of DPR toxicity that 
represent potential therapeutic targets.
In addition to the types of CRISPR knockout screens we used here, the CRISPR-Cas9 
system has been adapted to perform other types of genetic screens. Using Cas9 with a 
deactivated nuclease (dCas9), which is unable to generate double strand breaks, specific 
genomic regions can be targeted for transcriptional control 75,76. Fusing a KRAB effector 
domain to Cas9 results in transcriptional repression (CRISPRi, CRISPR interference) 77. 
Alternatively, CRISPRa (CRISPR activation) utilizes dCas9 fused with various 
transcriptional activation domains, empowering genome-wide transcriptional activation (i.e. 
overexpression) screens 76–79. Thus, the same logic of yeast, worm and fly genetic screens 
for up- or downregulation of genes can now be achieved in human cells on a genome-wide 
scale. Together, we anticipate that CRISPR screens in human cells and primary neurons will 
be a powerful addition to the experimental toolbox to study mechanisms of 
neurodegenerative disease.
Online Methods
Cell Culture
K562 cells (ATCC) were cultured in RPMI-1640 (Gibco) media with 10% fetal bovine 
serum (FBS) (Hyclone), penicillin (10,000 I.U./mL), streptomycin (10,000 μg/mL), and L-
glutamine (2 mM). Cells were grown in log phase by maintaining the population at a 
concentration of 500,000 cells per mL. K562 cells were maintained in a controlled 
humidified incubator at 37°C, with 5% CO2.
Primary mouse cortical neurons were dissociated into single cell suspensions from E16.5 
mouse cortices using a papain dissociation system (Worthington Biochemical Corporation). 
Neurons were seeded onto poly-L-lysine coated plates (0.1% w/v) and grown in Neurobasal 
media (Gibco) supplemented with B-27 serum-free supplement (Gibco), GlutaMAX, and 
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Penicillin-Streptomycin (Gibco) in a humidified incubator at 37°C, with 5% CO2. Half 
media changes were performed every 4–5 days, or as required. For gene silencing 
experiments in Cas9+ cortical neurons, lentiviruses encoding sgRNAs expressed from a U6 
promoter were transduced on DIV1. Cultures were allowed to incubate for at least 10 days 
with the sgRNAs in order to get adequate reduction of target protein levels before further 
experiments were performed.
Dorsal root ganglion cultures: 24 well plates were coated overnight with PDL (100 μg/ml) 
and following a water wash were coated with laminin (1.33 mg/ml) for at least 3 hours. 
DRGs were dissected from E12.5 mouse embryos and dissociated in 0.05% Trypsin-EDTA. 
Dissociated neurons were plated in Neurobasal supplemented with 2% B27, 0.45% D-
glucose, 1% GlutaMAX, 100U/ml penicillin, and 100U/ml streptomycin. On DIV1, the 
cultures were fed with fresh Neurobasal/B-27 medium containing 5μM 5-fluoro-2′-
deoxyuridine and 5μM uridine to inhibit the growth of non-neuronal cells. On DIV1, cells 
were transduced with lentivirus expressing sgRNAs targeting a safe genomic region (Safe) 
or TMX2 or Rab7. Cultures were treated with PR at 0.5 μM on DIV 10. For ATP 
measurement, neuronal cell bodies and proximal axon were removed, and axons were 
subjected to ATP measurement with Cell Titer Glo (Promega) or Caspase 3/7 Glo 
(Promega).
Generation of stable RAB7A knockdown cells: HeLa cells stably expressing dCas9 that is 
fused to a KRAB domain were infected with sgRNAs targeting RAB7A or a negative 
control sgRNA. Cells were selected with puromycin (1ug/mL) for stable sgRNA expression.
Lentivirus production
HEK293T (ATCC) cells were cultured under standard conditions (DMEM + 10% FBS + 
Penicillin-Streptomycin.) and used to package lentiviral particles following standard 
protocols with 3rd generation packaging plasmids. Lentiviral containing media was 
harvested after 48hrs., centrifuged at 300g for 5 min. to remove cellular debris, and 
concentrated 10-fold using Lenti-X concentrator (Clontech) before adding to cell cultures. 
GFP or PR50-FLAG constructs were cloned into a 3rd generation lentiviral vector that 
expresses the transgenes under the control of the neuron specific human synapsin 1 promoter 
(SYN).
Lentivirus production for iPSC derived motor neuron experiments: All shRNA and 
Hb9::RFP-encoding lentiviruses were produced as follows: HEK293T cells were transfected 
at 80–90% confluency with viral vectors containing the genes of interest and viral packaging 
plasmids (pPAX2 and VSVG for lentivirus) using polyethylenimine (PEI)(Sigma-Aldrich). 
The medium was changed 24h after transfection. Viruses were harvested at 48 and 72 hours 
after transfection. Viral supernatants were filtered with 0.45 μM filters and concentrated by 
incubating with Lenti-X concentrator (Clontech) for 24 hours at 4°C and centrifuging at 
1,500 × g at 4°C for 45 minutes. The pellets were resuspended in 300 μl DMEM + 10% FBS 
and stored at −80°C.
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Immunocytochemistry and antibodies
Cells were grown on poly-L-lysine coated glass coverslips (0.1% w/v) in standard multiwell 
cell culture plates and were stained using standard immunocytochemistry techniques. 
Briefly, cells were fixed with 4% formaldehyde, permeabilized with 0.1% Triton X-100, 
blocked with 5% normal goat serum, and stained with the following antibodies: mouse 
monoclonal anti-FLAG (1:1000, M2 Sigma cat.# F1804), mouse monoclonal anti-MAP2A 
(1:1000, Millipore cat.# MAB378), mouse monoclonal anti-V5 tag (1:500, Thermo Fisher 
Scientific cat.# R960-25), rabbit monoclonal anti-LAMP1 (1:200, Cell Signaling 
Technology, D2D11 cat.# 9091), or mouse monoclonal anti-NeuN (1:1000, Millipore cat.# 
MAB377). Coverslips were mounted using Prolong Diamond Antifade Mountant with DAPI 
(Thermo Fisher Scientific). Images were acquired using either a Leica DMI6000B inverted 
fluorescence microscope with a 40X oil immersion objective or a confocal Zeiss LSM710 
microscope with a 63X oil immersion objective. Percent area of MAP2 immunofluorescence 
staining was quantified using ImageJ. Images in a stack were thresholded and the % area of 
the signal for each image was measured.
DRG immunocytochemistry: Neuronal cultures were fixed in 4% (w/v) 
paraformaldehyde/PBS at room temperature for 15 min, followed by permeabilization with 
0.1% Triton X-100/PBS for 30 min. After blocking for 1 hour with 5% bovine serum 
albumin (BSA) / 0.1% Triton X-100 / PBS, axons were then stained with anti-Tuj1 (1:2000) 
in blocking buffer at 4ºC overnight. After washing two times with 0.1% Triton X-100 / PBS, 
axons were labeled with the appropriate Alexa-dye conjugated secondary antibodies (Life 
Technologies) for 2 hours at room temperature, washed three times with 0.1% Triton-
X-100 / PBS, and mounted in Fluoromount-G.
Genome-wide CRISPR-Cas9 screens in K562 cells
The 10-sgRNA per gene CRISPR/Cas9 deletion library was synthesized, cloned, and 
infected into Cas9 expressing K562 cells as previously described 44. Briefly ~300 million 
K562 cells stably expressing SFFV-Cas9-BFP were infected with the 10 guide/gene 
genome-wide sgRNA library at an MOI < 1. Infected cells underwent puromycin selection 
(1ug/mL) for 5 days after which point puromycin was removed and cells were resuspended 
in normal growth media without puromycin. After selection, sgRNA infection was measured 
by flow cytometry confirming that > 90% of cells were mCherry+. Sufficient sgRNA library 
representation was confirmed by deep sequencing after selection. Cells were maintained for 
three weeks at 1000× coverage (~1000 cells containing each sgRNA) at a concentration of 
500,000 cells/mL for the duration of each screen. Cells were split into two conditions: one 
control group that remained untreated, and one group that was treated with the respective 
synthetic DPR (PR20 at 8 μM or GR20 at 10 μM). This treatment occurred four times over 
three weeks, allowing for cells to recover to ~90% viability after each round of treatment. At 
the end of each screen genomic DNA was extracted for all screen populations separately 
according to the protocol included with QIAGEN Blood Maxi Kit and deep sequencing on 
an Illumina Nextseq was used to monitor library composition. Guide composition between 
PR or GR treated conditions was compared to the untreated condition using casTLE 45 
version 1.0 (see list of URLs). Briefly, the enrichment of individual guides was calculated as 
log ratios between treated and untreated conditions, and gene-level effects were calculated 
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from ten guides targeting each gene. A confidence score was then derived as a log-likelihood 
ratio describing the significance of the gene-level effect. P-values were then calculated by 
permutating the targeting guides as previously described 45.
K562 competitive growth assays
K562 cells stably expressing Cas9 were infected with sgRNAs targeting each gene of 
interest for validation from the genome wide screen. sgRNA plasmids also encoded for GFP 
expression. Cells were selected for stable sgRNA expression using puromycin (1 μg/mL) 
and were confirmed to be GFP positive before use in competitive growth assays. Equal 
numbers of GFP+/sgRNA expressing cells were co-cultured with wildtype/GFP- cells, and 
were subsequently treated with 8 μM PR20. The percentage of GFP+ cells were quantified by 
fluorescence activated cell sorting using a BD Accuri C6 flow cytometer after 48 hours.
Pre-treatment of ISRIB in PR20 exposed K562s
ISRIB (SIGMA SML0843) was dissolved in DMSO and added to the K562 cell line at a 
concentration of 15 nM 3 hours before treatment with PR20. An equal amount of DMSO was 
added to cells that did not get pre-treated with ISRIB. 15 μM of PR20 was then added to 
these cells and a third group of K562s were not treated with ISRIB or PR20 to serve as an 
untreated control. 24 hours after PR20 treatment cells were measured using the BD Accuri 
C6 flow cytometer for forward and side scatter analysis (FSC/SSC). All experiments were 
performed in triplicate.
CRISPR-Cas9 screen for DPR toxicity in primary mouse cortical neurons
Cortical tissue from mouse E.16.5 embryos [Gt(ROSA)26Sortm1.1(CAG-cas9*,-EGFP)Fezh/J; 
Jackson Laboratory Stock No: 024858] was dissected and dissociated into a single cell 
suspension using a papain dissociation system (Worthington Biochemical Corporation). 7 
million cells were seeded onto 10cm dishes respectively in Neurobasal media (Gibco) 
supplemented with B-27 serum-free supplement (Gibco), GlutaMAX (Gibco), and 
Penicillin-Streptomycin (Gibco). Half the culture media was replenished every 4–5 days. 
One day after seeding, neurons were infected with a lentiviral library containing ~3000 
sgRNA elements consisting of 178 genes (5% FDR for PR20 genome-wide screen hits), 10 
sgRNAs/gene, and 1,000 negative control sgRNAs, synthesized and cloned as previously 
described 45. Transductions were performed using a titer resulting in a 50–70% infection 
rate. Cas9-mediated genome editing was allowed to occur for 2 weeks in culture, after which 
PR20 synthetic dipeptides or PR50 expressing lentivirus were applied. Synthetic DPR screen: 
half the cells were left untreated (control group), and the other half were treated with 1.5 μM 
synthetic PR20 for 24hr, which resulted in approximately 90% cell death. Lentiviral 
mediated DPR screen: half the cells were infected with a control lentivirus expressing eGFP 
from the synapsin promoter (control group), and the other half were infected with a 
lentivirus expressing codon optimized PR50 from the synapsin promoter. Lentiviral PR50 
resulted in approximately 90% cell death between 4–6 days. To harvest DNA from the 
remaining live cells, cultures were washed 3 times in PBS, then treated with DNaseI 
(Worthington Biochemical Corporation) for 10 minutes at 37°C (to remove any extracellular 
gDNA from dead neurons), and then washed again 3 times in PBS to remove residual 
DNaseI. Genomic DNA was harvested using a DNeasy Blood and Tissue Kit (QIAGEN) 
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including Proteinase K digestion to inactivate residual DNaseI. sgRNA amplification and 
library preparation for deep sequencing was performed as described above. Gene-level 
effects and confidence scores were calculated as in the primary screen. The significance of 
the gene-level effects was determined using the 95% credible intervals calculated using 
casTLE 45. A gene was considered a hit if its 95% credible interval did not contain zero.
RNA-sequencing
Total RNA quality control was performed using the Eukaryote Total RNA Nano assay on the 
Agilent 2100 Bioanalyzer System for all RNA samples prior to library preparation for RNA 
sequencing. mRNA libraries were prepared for Illumina paired-end sequencing using the 
Agilent SureSelect Strand Specific RNA-Seq Library Preparation kit on an Agilent Bravo 
Automated Liquid Handling Platform. Libraries were sequenced on an Illumina NextSeq 
sequencer. Alignment of RNA-sequencing reads to the transcriptome was performed using 
STAR with ENCODE standard options, read counts were generated using rsem, and 
differential expression analysis was performed in R using DESeq2 package 80. All 
bioinformatics analyses were performed on Sherlock, a Stanford HPC cluster.
qRT-PCR
cDNA was reverse transcribed from total RNA samples using the High Capacity cDNA 
Reverse Transcription Kit (ThermoFisher Scientific). Taqman assays (Applied Biosystems) 
for ATF3, ATF4, ATF5, CHAC1, DDIT3, BBC3, and BAX were used in qPCR reactions 
using inventoried Taqman Universal PCR Master Mix (ThermoFisher Scientific) and a 
StepOne or QuantStudio 3 real time PCR machine. In order to measure XBP1 splicing, 
cDNA was generated as described above and equal amounts of cDNA (2 μl) were used in a 
PCR reaction using KOD polymerase (EMD Millipore cat.# 71086). Primers used in these 
experiments are listed in Supplementary Table 5. The cycling conditions were as follows: 
95°C for 5 min; 10 cycles of 94°C for 20 s, 65–55°C touchdown (−1 degree/cycle) for 20 s, 
and 72°C for 30 s; 35 cycles of 94°C for 20 s, 58°C for 20 s, and 72°C for 30 s, and a final 
extension at 72°C for 5 min. Products were analyzed using 2% agarose gel electrophoresis.
Western Blotting
Protein lysates were prepared using RIPA buffer supplemented with 1X Halt Protease 
Inhibitor Cocktail (Pierce). Crude lysates were centrifuged at 12,500g for 10 min. at 4°C to 
remove cellular debris. Clarified lysates were quantified using Pierce BCA protein assay. 
Equal amounts of protein were subjected to SDS-PAGE, transferred to nitrocellulose 
membranes, and immunoblotted following standard protocols. The following antibodies 
were used: mouse anti-GAPDH (1:5000, clone GAPDH-71.1, Sigma G8795), rabbit 
polyclonal anti-TMX2 (1:1000, Novus NBP1-87305), and rabbit polyclonal anti-XPO5 
(1:2000, Bethyl Laboratories A303-991A).
Cytotoxicity Assays
K562 cell viability after DPR treatment was measured by flow cytometry using a BD Accuri 
C6 flow cytometer by measuring number of events in forward scatter and side scatter gates. 
Cytotoxicity in primary neuron cultures was measured both by lactose dehydrogenase 
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(LDH) release assays (Promega, CytoTox 96® Non-Radioactive Cytotoxicity Assay) and by 
NeuN+ quantification of surviving neurons using immunocytochemistry. To quantify 
numbers of NeuN+ neurons, cells were fixed and stained as described above, and quantified 
using ImageJ. Briefly, thresholds were applied to image stacks in order to detect NeuN 
positive neuronal nuclei, which were then automatically counted using built in ImageJ 
plugins. Additional cytotoxic assays were performed using the Caspase-Glo 3/7 Assay 
(Promega cat.# G8090), a luminescence based readout of caspase 3/7 activity (DEVDase 
activity) in neurons according to the manufacturer’s instructions.
Virus production for induced motor neuron experiments
Complementary DNAs (cDNAs) for the induced motor neuron (iMN) factors (Ngn2, Lhx3, 
Isl1, NeuroD1, Ascl1, Myt1l, and Brn2) were purchased from Addgene. Each cDNA was 
cloned into the pMXs retroviral expression vector using Gateway cloning technology 
(Invitrogen). The Hb9::RFP lentiviral vector was also purchased from Addgene (ID: 37081). 
Viruses were produced as follows: HEK293 cells were transfected at 80–90% confluency 
with viral vectors containing genes of interest and viral packaging plasmids (PIK-MLV-gp 
and pHDM for retrovirus; pPAX2 and VSVG for lentivirus) using polyethylenimine (PEI)
(Sigma-Aldrich). The medium was changed 24h after transfection. Viruses were harvested at 
48 hours and 72 hours after transfection. Viral supernatants were filtered with 0.45 μM 
filters, incubated with Lenti-X concentrator (Clontech) for 24 hours at 4 °C, and centrifuged 
at 1,500 × g at 4°C for 45 min. The pellets were resuspended in 300 μl DMEM + 10% FBS 
and stored at −80 °C.
Generation of Dox-NIL induced motor neurons
To generate Dox-NIL iMNs, the Dox-NIL construct was integrated into the AAVS1 safe 
harbor locus of the control and C9-ALS patient iPSC lines using CRISPR/Cas9 editing 
(gRNA sequence shown in Supplementary Table 4). The Conversion of NIL-iMNs was 
performed in 96-well plates (2 × 103 cells/well), which was sequentially coated with 
matrigel (1 hour) and laminin (2–4 hours) at room temperature. iPSCs were cultured in 
mTeSr and induced with 1 μg/ml doxycycline on day 1 after plating. On day 3 after plating, 
the culture was transduced with CTRL shRNA1, CTRL shRNA2, TMX2 shRNA1 and 
TMX2 shRNA2 with 5 μg/ml polybrene in N3 media containing DMEM/F12 (Life 
Technologies), 2% FBS, 1% penicillin/streptomycin, N2 and B27 supplements (Life 
Technologies), and 10 ng/ml each of GDNF, BDNF, and CNTF (R&D). For the detection of 
the motor neurons, the culture was transduced with Hb9::RFP reporter 48 hours after shRNA 
transduction. On day 5, primary mouse cortical glial cells from P1 ICR pups (male and 
female) were added to the transduced cultures in N3 media.
Generation of 7 transcription factors (7F) induced motor neurons
Reprogramming was performed in 96-well plates (8 × 103 cells/well) that were sequentially 
coated with gelatin (0.1%, 1 hour) and laminin (2–4 hours) at room temperature. To enable 
efficient expression of the transgenic reprogramming factors, iPSCs were cultured in 
fibroblast medium (DMEM + 10% FBS) for at least 48 hours and either used directly for 
retroviral transduction or passaged before transduction for each experiment. 7 iMN factors 
were added in 100–200 μl fibroblast medium per 96-well well with 5 μg/ml polybrene. For 
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iMNs, cultures were transduced with lentivirus encoding the Hb9::RFP reporter 48 hours 
after transduction with transcription factor-encoding retroviruses. On day 5, primary mouse 
cortical glial cells from P1 ICR pups (male and female) were added to the transduced 
cultures in glia medium containing MEM (Life Technologies), 10% donor equine serum 
(HyClone), 20% glucose (Sigma-Aldrich), and 1% penicillin/streptomycin. On day 6, 
cultures were switched to N3 medium containing DMEM/F12 (Life Technologies), 2% FBS, 
1% penicillin/streptomycin, N2 and B27 supplements (Life Technologies), 7.5 μM RepSox 
(Selleck), and 10 ng/ml each of GDNF, BDNF, and CNTF (R&D). The iMN neuron cultures 
were maintained in N3 medium, changed every other day, unless otherwise noted.
Induced motor neuron survival assay
Hb9::RFP+ neurons appeared between days 10–13 after initial seeding. The doxycycline 
was withdrawn at day 10 and the survival assay was initiated at day 20. For the glutamate 
treatment, 10 μM glutamate was added to the culture medium on day 20 and removed after 
24 hours. Longitudinal tracking was performed by imaging neuronal cultures in a Nikon 
Biostation CT once every 24 hours starting at day 20. Tracking of neuronal survival was 
performed using SVcell 3.0 (DRVision Technologies). Neurons were scored as dead when 
their soma was no longer detectable by RFP and GFP fluorescence. All neuron survival 
assays were performed at least twice, with one of the trials being used for the quantification 
shown. All trials quantified were representative of other trials of the same experiment. When 
iMNs from multiple independent donors are combined into one survival trace in the Kaplan-
Meier plots for clarity, the number of iMNs tracked from each line can be found in 
Supplementary Table 4.
Statistics
Statistical tests were performed using GraphPad Prism 7. Two-tailed t-tests, one-way 
ANOVAs, or log-rank tests for survival curves were used as indicated.
Data Availability
RNA sequencing data from this study have been deposited with NCBI GEO with the 
accession code: GSE109177
The data supporting the findings of this study are available from the corresponding author 
upon reasonable request.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Genome-wide CRISPR-Cas9 knockout screens in human cells identify modifiers of 
C9orf72 DPR toxicity
FLAG-tagged synthetic DPRs (PR20 or GR20) were added to the culture media of K562 
cells, and dose-dependent cytotoxicity was measured using flow cytometry (a, c). The DPRs 
were internalized and localized to the nucleus of cells as visualized by 
immunocytochemistry (b, d, blue = DAPI, green = anti-FLAG, scale bar = 10μm). (e) 
Pooled CRISPR-Cas9 screening paradigm. K562 cells stably expressing Cas9 were infected 
with a lentiviral sgRNA library (10 sgRNAs/gene), the population was split and half the cells 
were treated with PR20 or GR20 for 4 pulses (at concentrations sufficient to kill 50% of cells 
each pulse), and then the resulting populations were subjected to deep sequencing and 
analysis. Screens were repeated 2 independent times for each DPR. (f) Volcano plot for all 
human genes in the GR20 screen. Colored in blue are all the gene conferring resistance to 
GR20 when knocked out (10% FDR) and colored in red are all the genes conferring 
sensitivity to GR20 when knocked out (10% FDR). (g) Correlation of signed confidence 
scores of significant hits between GR20 and PR20 screens (R2 = 0.61). (h) Validation of hits 
using independently generated single gene knockout K562 lines in co-culture competitive 
growth assays. Equal numbers of knockout cells (GFP+) and WT control cells (GFP−) were 
co-cultured in equal starting numbers and subsequently treated with PR20 (10 μM). The 
abundance of knockout cells (GFP+ cells) was quantified by flow-cytometry 48 hours after 
PR20 treatment and compared to the untreated population (n = 3, two-tailed t-test; *** p < 
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0.001, ** p < 0.01; error bars are ± S.D.) Each gene was validated using two distinct 
sgRNAs.
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Figure 2. Summary of modifiers identified from genome-wide knockout screens in K562 cells
Schematic of selected hits (10% FDR) from both PR20 and GR20 screens colored coded by 
significance (p-value) and depicted at subcellular localizations based on gene ontology.
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Figure 3. CRISPR-Cas9 knockout screens in primary mouse neurons
(a) Synthetic PR20 added to primary neuron cultures caused dose-dependent cytotoxicity 
within 24 hours measured by lactose dehydrogenase (LDH) release or counts of surviving 
NeuN+ neuronal nuclei by immunocytochemistry (two-tailed t-test; **** p < 0.0001, *** p 
< 0.001, ** p < 0.01; error bars are ± S.E.M). (b) Expression of PR50 using lentiviral 
transductions caused time dependent cytotoxicity measured by LDH release or counts of 
surviving NeuN+ neuronal nuclei by immunocytochemistry (two-tailed t-test; **** p < 
0.0001, *** p < 0.001, ** p < 0.01; error bars are ± S.E.M). (c) CRISPR-Cas9 screening 
paradigm in primary mouse neuron cultures. Cortical neurons were plated and infected with 
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sgRNA libraries (~200 genes passing a 5% FDR cutoff from the genome-wide PR screen 
with 10 sgRNAs/gene + ~1000 negative control sgRNAs). Four independent screening 
conditions were conducted, each in replicate: synthetic PR20 treated neurons (1.5μM, 
overnight), untreated neurons, lentiviral expression of PR50 (5 days), and lentiviral 
expression of GFP (5 days) as a control. The abundance of sgRNAs in the surviving cells 
was measured by sgRNA deep sequencing. PR50 localized to the nucleus of cultured neurons 
(blue = DAPI, red = anti-FLAG (PR50), green = anti-MAP2). (d, e) Volcano plots of effect 
scores and confidence scores of all genes for each screen. Effect and confidence scores are 
calculated using casTLE 45. The effect score is a gene-level summary of how protective or 
sensitizing the knockout is, while the confidence score is a log-likelihood ratio describing 
the significance of the effect. Genes were designated hits if their 95% credible intervals 
derived from casTLE did not contain zero; 13 genes in the synthetic PR20 screen and 17 
genes in the lentiviral PR50 screen passed this criteria (Supplementary Table 2).
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Figure 4. Validation of RAB7 and TMX2 as modifiers of PR toxicity in an independent neuronal 
culture system
(a) Dorsal root ganglion (DRG) axon degeneration was evaluated by Tuj1 
immunocytochemistry in the presence of 0.5 μM PR20 in cultures transduced with sgRNAs 
targeting a control genomic region, Tmx2, or Rab7. DRG axon degeneration was further 
quantified by caspase 3/7 activity (b), ATP levels (c), and an apoptotic index (d), which is 
the ratio of active caspase 3/7:ATP levels (one-way ANOVA, Dunnett’s multiple 
comparisons test, *** p < 0.001, ** p < 0.01; error bars are ± S.E.M).
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Figure 5. Transcriptional analysis of PR treated primary neurons and K562 cells reveals ER 
stress signatures
(a) RNA sequencing of primary mouse neurons treated with lentiviruses expressing either 
PR50 or GFP under control of the synapsin promoter for 4 days. Differentially expressed 
genes were determined using DESeq2. (b) MA plot of differential gene expression of PR50 
expressing neurons compared to control GFP expressing neurons (red = significantly 
upregulated genes, adjusted p-value < 0.05; blue = significantly down regulated genes, 
adjusted p-value < 0.05). (c) Selected gene ontology (GO) terms enriched within 
significantly upregulated genes (red) or significantly downregulated genes (blue) determined 
using DAVID 6.8. (d) Fold change in expression of select genes that were found to be 
significantly differentially expressed by DESeq2 (n = 3, adjusted p-value < 0.001; error bars 
are ± S.E.M) grouped by GO category. (e) qRT-PCR validation of Atf4, Atf5, Chac1, Ddit3, 
and Bbc3 upregulation in neurons expressing PR50 for 3, 4, or 5 days compared to control 
neurons. (f) RNA sequencing in K562 cells treated for 24 hours with synthetic PR20 also 
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show upregulation of ER stress related genes. Relative expression of significantly 
differentially expressed genes determined by DESeq2 (n = 3, adjusted p-value < 0.001; error 
bars are ± S.D.) plotted using FPKMs for each gene relative to the untreated population of 
cells. (g) K562 cells pre-incubated with 15nM ISRIB or equal amounts of DMSO were 
treated with 15 μM PR20 (red) or untreated (black) for 24 hours, then measured for viability 
by flow cytometry (FSC/SSC). Each measurement was performed in triplicate with mean 
and SD plotted by error bars (** p-value < 0.005, two-tailed t-test). (h) Reverse transcriptase 
PCR analysis to measure amounts of spliced XBP1 mRNA (relative to GAPDH levels) in 
cortical neurons transduced with PR50 for 3, 4, or 5 days (+ Thaps. = 200 nM thapsigargin 
treatment, 2hr.).
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Figure 6. Tmx2 reduction is protective against PR mediated toxicity by modulating the ER stress 
response and improves the survival of C9orf72 ALS patient derived motor neurons
(a) Tmx2 protein levels measured in primary Cas9+ cortical neurons by immunoblot 10 days 
post sgRNA transduction (uncropped blot images are shown in Supplementary Data Set 1). 
(b) Quantification of lactose dehydrogenase levels (LDH) in primary cortical neurons 5 days 
post-transduction with PR50 or GFP lentiviruses as a measurement of cytoxicity. Tmx2 
reduction by sgRNA lentivirus transduction on DIV1 (TMX2 sgRNA) protected primary 
neurons against PR50 induced cytotoxicity relative to control infected neurons (Safe sgRNA) 
(one-way ANOVA; n = 3; * p < 0.05; error bars are ± S.E.M). (c) Quantification of activated 
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caspase 3/7 (DEVDase activity; RLU = relative light units) in primary neurons 4 days post-
transduction with PR50 or GFP lentiviruses (n = 3–4, one-way ANOVA, Dunnett’s multiple 
comparisons test, ** p < 0.01). (d) RNA-seq analysis of neurons infected with Safe or 
TMX2 targeting sgRNAs 4 days post-transduction with PR50 or GFP lentiviruses. Log2 fold 
change (TMX2 sgRNA/Safe sgRNA in PR50 treated conditions) of differentially expressed 
genes determined using DESeq2 (n = 3; adjusted p-value < 0.001; error bars are ± S.E.M.) 
enriched in select GO categories (e) Select GO term enrichment determined using DAVID 
6.8 (red = upregulated genes, blue = downregulated genes) of differentially expressed genes 
(adjusted p-value < 0.001) determined by comparing RNA-seq results between control (Safe 
sgRNA) and Tmx2 KO (TMX2 sgRNA) neuron cultures expressing PR50. (f) qRT-PCR 
validation of Atf3 expression changes after PR50 expression in control (Safe sgRNA) and 
Tmx2 KO (TMX2 sgRNA) neurons (n = 3; p < 0.0001; one-way ANOVA; error bars are ± 
S.E.M.). (g) V5-tagged ATF3 overexpression by lentiviral transduction of primary cortical 
neurons confers protection of PR50 induced dendrite degeneration, as measured by 
immunocytochemistry (blue = DAPI, green = anti-MAP2 (dendrite marker), magenta = anti-
V5 (ATF3-V5 overexpression), SYN = lentiviral synapsin promoter, scale bar = 20μm). (h) 
Quantification of % area of MAP2 immunofluorescence (n=5, one-way ANOVA, Dunnett’s 
multiple comparisons test, *** p < 0.001). (i) Quantification of active caspase 3/7 
(DEVDase) in PR50 or GFP expressing cortical neurons with or without ATF3 
overexpression (n=5, one-way ANOVA, Dunnett’s multiple comparisons test, (**** p < 
0.0001).
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Figure 7. Reduction of TMX2 improves the survival of C9-ALS iPSC derived induced motor 
neurons
Quantification of surviving motor neurons with or without TMX2 reduction by lentiviral 
shRNA transduction in two independent C9-ALS iPSC lines (a = C9-ALS line 1, b = C9-
ALS line 2). Induced motor neurons were generated from iPSCs using a seven factor (7F) 
differentiation system. The survival of HB9-RFP+/shRNA-GFP+ iMNs was tracked by 
imaging after the addition of 10 μM glutamate to the cultures. All iMN survival experiments 
were analyzed by log-rank test, and statistical significance was calculated using the entire 
survival time course. * p < 0.05, ** p < 0.01, **** p < 0.0001 (survival assays were 
performed in triplicate with the indicated number of iMNs analyzed for each group, 
Supplementary Table 4).
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